NCT00908310

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

A Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive OMNISCAN (Gadodiamide Injection) for Contrast-enhanced Magnetic Resonance Imaging.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 213 (actual)
• Sponsor: GE Healthcare · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI. Omniscan will be administered intravenously at the medical discretion of the prescribing physician.

Conditions

• Chronic Kidney Disease
• Renal Insufficiency

Interventions

Type	Name	Description
DRUG	Omniscan	OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.

Timeline

• Start date: 2009-05-01
• Primary completion: 2013-06-01
• Completion: 2013-09-01
• First posted: 2009-05-25
• Last updated: 2014-07-17
• Results posted: 2014-07-17

Locations

1 site across 1 country: United States